曲美布汀杂质B | 144095-19-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 曲美布汀杂质B
• 英文名称: rac-α-ethyl-phenylglycine
• 英文别名: 2-amino-2-phenylbutanamide；2-Amino-2-phenyl-butyramid
• CAS: 144095-19-2
• 化学式: C₁₀H₁₄N₂O
• 分子量: 178.234
• InChiKey: YCPTZRUVAHGKMX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  69.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  曲美布汀杂质B 以9%的产率得到(S)-(+)-2-氨基-2-苯基丁酸
  参考文献：
  名称：

  Enzymatic resolution of α,α-disubstituted α-amino acid esters and amides

  摘要：

  The scope and limitations of the enzymatic resolution of alpha,alpha-disubstituted alpha-amino acid amides by an amino acid amidase from Mycobacterium neoaurum and of the corresponding ethyl esters with Pig liver esterase (PLE) have been studied. Moderate enantiomeric excesses were obtained with PLE, with only a narrow substrate specificity. Mycobacterium neoaurum on the contrary yields a broad range of S-alpha,alpha-disubstituted alpha-amino acids 1 and the corresponding R-amides 2.

  DOI：

  10.1016/s0957-4166(00)80217-7

文献信息

• Efficient Biocatalytic Synthesis of Highly Enantiopureα-Alkylated Arylglycines and Amides
  作者：Mei-Xiang Wang、Shuan-Jun Lin、Jun Liu、Qi-Yu Zheng

  DOI：10.1002/adsc.200303219

  日期：2004.3

  racemic α-alkylarylglycine amides including 1-amino-1-carbamoyl-1,2,3,4-tetrahydronaphthalene underwent efficient biocatalytic hydrolysis under very mild conditions to afford the corresponding (S)-α-alkylarylglycines and (R)-α-alkylarylglycine amides in excellent yields with enantiomeric excesses higher than 99.5%. Both the reaction rate and enantioselectivity of biocatalytic kinetic resolution were strongly

  包括1-氨基-1-氨基甲酰基-1,2,3,4-四氢萘在内的许多外消旋α-烷基芳基甘氨酸酰胺在非常温和的条件下进行了有效的生物催化水解，得到相应的（S）-α-烷基芳基甘氨酸和（R）- α-烷基芳基甘氨酸酰胺具有优异的收率，对映体过量高于99.5％。生物催化动力学拆分的反应速率和对映选择性都强烈取决于取代基的性质和底物苯环上的取代方式。相反，在含腈水化酶/酰胺酶的微生物红球菌的催化下，未观察到源自苯乙酮的Strecker腈的有效生物转化。sp。AJ270全细胞催化剂。结合酰胺的化学水解，该生物转化过程从容易获得的外消旋酰胺提供了两种对映体形式的α-取代的芳基甘氨酸的有效合成。
• 4-substituted quinoline derivatives
  申请人：Neurogen Corporation

  公开号：US06413982B1

  公开（公告）日：2002-07-02

  Disclosed are compounds of the Formula where R1, R2, R3, R4, X, Y1, and Y2 are defined herein. These compounds bind with high affinity to NK-3 receptors and/or GABAA receptors. Also provided are pharmaceutical compositions comprising these compounds, and methods of treating patients suffering from various central nervous system and peripheral diseases or disorders with these pharmaceutical compositions. This invention also relates to the use of such compounds in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. The compounds of this invention are also useful as probes for the localization of NK-3 receptors and GABAA receptors.

  揭示了具有以下式的化合物，其中R1、R2、R3、R4、X、Y1和Y2在此处被定义。这些化合物与NK-3受体和/或GABAA受体具有高亲和力结合。还提供了包括这些化合物的药物组合物，以及使用这些药物组合物治疗患有各种中枢神经系统和外周疾病或障碍的患者的方法。本发明还涉及将这些化合物与一个或多个其他中枢神经系统药剂结合以增强其他中枢神经系统药剂效果的用途。本发明的化合物还可用作定位NK-3受体和GABAA受体的探针。
• Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors
  申请人：Allen George David

  公开号：US20070111995A1

  公开（公告）日：2007-05-17

  The invention provides pyrazolo[3,4-b]pyridine compounds of formula (I) having a —C(O)—NH—C(R 4 )(R 5 )-aryl substituent at the 5-position of the pyrazolo[3,4-b]pyridine ring system wherein at least one of R 4 and R 5 is not a hydrogen atom (H) compound or a salt thereof: wherein Ar has the sub-formula (x) or (z). These compounds are useful as inhibitors of PDE4.

  本发明提供了式(I)的吡唑并[3,4-b]吡啶化合物，其在吡唑并[3,4-b]吡啶环系的5位具有—C(O)—NH—C(R4)(R5)-芳基取代基，其中R4和R5中至少有一个不是氢原子（H）化合物或其盐：其中Ar具有亚式（x）或（z）。这些化合物可用作PDE4的抑制剂。
• 4-Substituted quinoline derivatives
  申请人：Neurogen Corporation

  公开号：US06624175B2

  公开（公告）日：2003-09-23

  Disclosed are compounds of the Formula where R1, R2, R3, R4, X, Y1, and Y2 are defined herein. These compounds bind with high affinity to NK-3 receptors and/or GABAA receptors. Also provided are pharmaceutical compositions comprising these compounds, and methods of treating patients suffering from various central nervous system and peripheral diseases or disorders with these pharmaceutical compositions. This invention also relates to the use of such compounds in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. The compounds of this invention are also useful as probes for the localization of NK-3 receptors and GABAA receptors.

  本发明涉及的化合物具有下列式中所定义的R1、R2、R3、R4、X、Y1和Y2。这些化合物与NK-3受体和/或GABAA受体结合亲和力高。本发明还提供了包含这些化合物的制药组合物以及使用这些制药组合物治疗患有各种中枢神经系统和周围疾病或疾病的患者的方法。本发明还涉及使用这种化合物与一个或多个其他中枢神经系统药物结合以增强其他中枢神经系统药物的效果。本发明所述的化合物还可用作定位NK-3受体和GABAA受体的探针。
• PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS
  申请人：Allen David George

  公开号：US20080132536A1

  公开（公告）日：2008-06-05

  The invention provides a compound of formula (I) or a salt thereof: wherein Ar has the sub-formula (x) or (z): and wherein R 3 is optionally substituted C 3-8 cycloalkyl, optionally substituted C 5-7 cycloalkenyl, an optionally substituted heterocyclic group (aa), (bb) or (cc), or a bicyclic group (ee); and wherein R 4 is H, C 1-3 alkyl, C 1-2 fluoroalkyl, cyclopropyl, —CH 2 OR 4a , —CH(Me)OR 4a , or —CH 2 CH 2 OR 4a ; and R 5 is inter alia H, C 1-8 alkyl, C 1-3 fluoroalkyl, C 3-8 cycloalkyl, certain substituted alkyl groups, —(CH 2 ) n 13 -Het, or optionally substituted phenyl or —CH 2 -Ph; or R 4 and R 5 taken together are —(CH 2 ) p 1 — or —(CH 2 ) p 3 —X 5 —(CH 2 ) p 4 —; provided that at least one of R 4 and R 5 is not a hydrogen atom (H). The invention also provides the use of the compounds as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, allergic rhinitis or atopic dermatitis.

  该发明提供了式(I)的化合物或其盐： 其中Ar具有亚式(x)或(z)： 其中，R3是可选的取代C3-8环烷基，可选的取代C5-7环烯基，可选的取代的杂环基(aa)，(bb)或(cc)，或者是双环基(ee)； 其中，R4是氢，C1-3烷基，C1-2氟代烷基，环丙基，—CH2OR4a，—CH(Me)OR4a或—CH2CH2OR4a； 而R5则是包括氢、C1-8烷基、C1-3氟代烷基、C3-8环烷基、某些取代烷基、—(CH2)n13-Het，或可选取代的苯基或—CH2-Ph等的基团； 或者，R4和R5在一起是—(CH2)p1—或—(CH2)p3—X5—(CH2)p4—； 但是至少其中一个R4和R5不是氢原子（H）。 该发明还提供了将这些化合物用作磷酸二酯酶IV（PDE4）的抑制剂和/或用于治疗和/或预防炎症和/或过敏性疾病，如慢性阻塞性肺疾病（COPD）、哮喘、类风湿性关节炎、过敏性鼻炎或特应性皮炎的用途。